
Claims

What is claimed is


1. A compound of Formula (I)



;

or pharmaceutically acceptable salt thereof.

2. A compound of Formula (I-a) according to claim 1



;

or pharmaceutically acceptable salt thereof.

3. The compound according to claim 2, wherein the compound is substantially enantiomerically pure.
4. A compound according to claim 1 selected from a group consisting of:

2-[[3-[(1R,2R)-2-hydroxy-2-methyl-cyclobutoxy]-1-methyl-pyrazol-4-yl]amino]-7-[(1S)-2-methoxy-1-methyl-ethyl]pyrrolo[2,3-d]pyrimidine-6-carbonitrile;

2-[[3-[(1S,2S)-2-hydroxy-2-methyl-cyclobutoxy]-1-methyl-pyrazol-4-yl]amino]-7-[(1S)-2-methoxy-1-methyl-ethyl]pyrrolo[2,3-d]pyrimidine-6-carbonitrile;

2-[[3-[trans-2-hydroxy-2-methyl-cyclobutoxy]-1-methyl-pyrazol-4-yl]amino]-7-[(1S)-2-methoxy-1-methyl-ethyl]pyrrolo[2,3-d]pyrimidine-6-carbonitrile;

2-[[3-[(1R,2S)-2-hydroxy-2-methyl-cyclobutoxy]-1-methyl-pyrazol-4-yl]amino]-7-[(1S)-2-methoxy-1-methyl-ethyl]pyrrolo[2,3-d]pyrimidine-6-carbonitrile;

2-[[3-[(1S,2R)-2-hydroxy-2-methyl-cyclobutoxy]-1-methyl-pyrazol-4-yl]amino]-7-[(1S)-2-methoxy-1-methyl-ethyl]pyrrolo[2,3-d]pyrimidine-6-carbonitrile;

2-[[3-[cis-2-hydroxy-2-methyl-cyclobutoxy]-1-methyl-pyrazol-4-yl]amino]-7-[(1S)-2-methoxy-1-methyl-ethyl]pyrrolo[2,3-d]pyrimidine-6-carbonitrile; and

2-[[3-[2-hydroxy-2-methyl-cyclobutoxy]-1-methyl-pyrazol-4-yl]amino]-7-[(1S)-2-methoxy-1-methyl-ethyl]pyrrolo[2,3-d]pyrimidine-6-carbonitrile;

or pharmaceutically acceptable salt thereof.

5. A pharmaceutical composition comprising a compound of any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
6. A medicament, characterized in that it comprises a compound of formula (I) according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof.
7. A compound of formula (I) according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, for use in the treatment of a neurodegenerative disease, for instance wherein the neurodegenerative disease is selected from the group consisting of Parkinson's disease, multiple sclerosis, HIV-induced dementia, amyotrophic lateral sclerosis, Lewy body dementia, Pick disease, progressive supranuclear palsy, and frontotemporal dementia.
8. A compound of formula (I) for use according to claim 7, or a pharmaceutically acceptable salt thereof, wherein the neurodegenerative disease is Parkinson' s disease.
9. A solid form of a compound of Formula (I-a) as defined in claim 2, characterized as crystalline Form A.

10. The solid form according to claim 9, which is at least 50% crystalline form, such as at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% crystalline.

11. The solid form according to claim 9 or claim 10, having an X-ray powder diffraction (XRPD) pattern derived using Cu (Kα) radiation comprising three, four, five, six, seven or more peaks, in term of 2-theta degrees, chosen from peaks at 6.8 ± 0.2, 9.8 ± 0.2, 13.6 ± 0.2, 13.9 ± 0.2, 14.7 ± 0.2, 16.0 ± 0.2, 17.4 ± 0.2, 17.8 ± 0.2, 19.3 ± 0.2, 19.9 ± 0.2, for instance having an XRPD pattern derived using Cu (Kα) radiation, in term of 2-theta degrees, having peaks at 6.8 ± 0.2, 17.8 ± 0.2, and 19.9 ± 0.2, such as having an X-ray powder diffraction pattern that is substantially in accordance with that shown in Figure 2.

12. The solid form according to any one of claims 9 to 11, characterized by a differential scanning calorimetry (DSC) curve with an onset at 118°C ± 2 °C, for instance characterized by a DSC profile substantially in accordance with that shown in Figure 1.

13. The solid form according to any one of claims 9 to 12, wherein Form A is characterized by at least two of:

a) an X-ray powder diffraction (XRPD) pattern substantially in accordance with that shown in Figure 2;

b) an X-ray powder diffraction (XRPD) pattern derived using Cu (Kα) radiation comprising three, four, five, six, seven or more peaks, in term of 2-theta degrees, at 6.8 ± 0.2, 9.8 ± 0.2, 13.6 ± 0.2, 13.9 ± 0.2, 14.7 ± 0.2, 16.0 ± 0.2, 17.4 ± 0.2, 17.8 ± 0.2, 19.3 ± 0.2, 19.9 ± 0.2;

c) a DSC profile substantially the same as shown in Figure 1;

d) a Differential Scanning Calorimetry (DSC) thermogram having an onset at 118 °C ± 2 °C;

e) a profile substantially the same as shown in Figure 3;

14. A pharmaceutical composition comprising the solid form as defined in any one of claims 9-13 and a pharmaceutically acceptable carrier.

15. A solid form as defined in any one of claims 9-13 for use in treating a neurodegenerative disease in a patient in need thereof.

16. Use of a solid form as defined in any one of claims 9-13 in the manufacture of a medicament for treating a neurodegenerative disease.